Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
Calithera Biosciences, Inc. (CALA)
Last calithera biosciences, inc. earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
calithera.com
Company Research
Source: GlobeNewswire
-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical
Show less
Read more
Impact Snapshot
Event Time:
CALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALA alerts
High impacting Calithera Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CALA
News
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat